Skip to contentI
Interpace Biosciences, Inc.
I
IDXGInterpace Biosciences, Inc. Q1 2022 · 10-Q
Revenue$7.92M$7.92M−19.4% vs Q1 2021 Net Income-$2.25M-$2.25MN/M vs Q1 2021 EPS Diluted-$0.53-$0.53N/M vs Q1 2021 Gross Profit$4,658,000+3.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Interpace Biosciences, Inc. · CIK 1054102 · Engraved from SEC EDGAR
Operating Cash Flow-$1,254,000N/M Free Cash Flowderived-$1,273,000— Margins · derivedGross margin58.8%+12.9 pt vs Q1 2021
Operating margin-12.3%+26.5 pt vs Q1 2021
Net margin-28.4%+14.4 pt vs Q1 2021
ended Mar 31, 2022 · filed May 16, 2022 · 46 d after period end